Introduction
Neuroblastoma (NB) is a childhood tumor of the sympathetic nervous system accounting for 8-10% of all childhood malignancies (Westermann and Schwab, 2002; Brodeur, 2003; Schwab et al., 2003; van Noesel and Versteeg, 2004) . The International Neuroblastoma Staging System (INSS) places patients under 1 year of age or with lower stage diseases (stages 1 (ST1) and 2 (ST2)) in the better outcome group as opposed to older patients, or those with advanced stage diseases (stages 3 (ST3) and 4 (ST4)). To date, the most reliable molecular prognostic indicator in NB is the amplification of the MYCN gene, found in 20-30% of NBs (Westermann and Schwab, 2002; Schwab et al., 2003; Tonini and Romani, 2003) . The correlation between the expression level of MYCN and the proliferative activity of NB cells has been shown both in vitro using flow cytometry (Cohn et al., 1990; Dominici et al., 1992) and in vivo (Schweigerer et al., 1990; Negroni et al., 1991; Schmidt et al., 1994) . The elevated expression of MYCN has also been shown to induce the expression of a significant number of ribosomal proteins (RP) in NB cell lines as well as tumors (Boon et al., 2001) , suggesting that the genes of the protein synthesis machinery are a major target of the MYCN protein.
A recent study involving expression profiling of primarily advanced stage NB tumors has provided a broad view of the NB transcriptome and identified a few potential players associated with MYCN (Alaminos et al., 2003) . In our study, we have expanded expression analysis of NB to tumors of ST1-4, with and without MYCN amplification. We developed a principal component analysis (PCA)-based approach to data analysis, which allows one to associate gene expression profiles with gene ontology (GO) annotations to identify the potential biological processes occurring within the transcriptome of NB. Our analysis demonstrates that in the absence of MYCN amplification, ST4 tumors are characterized by increased expression of the genes involved in the cell cycle, which distinguishes them from all lower stage tumors, including ST3, and that these genes are further upregulated in the MYCN-amplified (NB MYCN-AMP ) tumors.
Results

Identification of stage-specific expression signatures in NB tumors
Gene expression profiling was performed on 103 NB samples consisting of 23 ST1, 18 ST2, 20 ST3 and 42 ST4 tumors using a 42 578-clone cDNA microarray. Of these tumors, 21 were NB MYCN-AMP (17 ST4, four ST3 and one of ST2). PCA was used on the gene expression data to reduce the dimensionality and visually classify the tumors according to stage and MYCN amplification. In this data set, PC1 captured 28% of the total variance and represents the patterns of maximum overall difference among the tumors. However, no separation of tumor types is observed in the PC1 dimension, as shown on Figure 1a , where the tumors are plotted in the space of the first two principal components (PC1 and PC2). The separation of ST1 tumors from ST4 and NB MYCN-AMP tumors is achieved only in the PC2 dimension, which captures 11% of the variance. In addition, there is a significant degree of separation between ST4 tumors according to their MYCN amplification status. Therefore, based on the PC2 coordinate, we can distinguish ST1 from ST4 or MYCN notamplified (NB MYCN-NA ) tumors from NB MYCN-AMP .
Next, we identified the differentially expressed genes in NB MYCN-NA tumors using a one-way ANOVA for the tumors of ST1-4 and identified 6103 clones with P-values less than 0.05. Figure 1b shows the PCA plot using these 6103 clones, and as expected, the stages are now more clearly separated along PC1 since we have subselected differentially expressed genes. We find clear separation of ST1 from ST4 and some separation from ST3 tumors. ST2 samples were markedly heterogeneous but the majority clustered with ST1 tumors, and ST3 tended to cluster between ST1 and ST4, although there was considerable admixture in these tumors along PC1. Figure 1c shows the PC1 values plotted using the median gene expression levels in each of the subgroups for these 6103 genes and gives a graphical depiction of the increasing variance as the tumors progress from ST1 to ST4.
In order to identify which of these 6103 clones distinguish one stage from another, we next performed a pairwise permutation t-test using these clones (see Materials and methods) on all combinations of stages of NB ST1 vs ST3, ST1 vs ST4, ST2 vs ST3, ST2 vs ST4 and ST3 vs ST4 for NB MYCN-NA tumors (Table 1) . In this analysis, a gene was considered differentially expressed when the adjusted P-value obtained in the pairwise permutation t-test was less than 0.05, irrespective of the fold-change in gene expression (see Materials and methods). This analysis found differentially expressed genes representing 1434 distinct UniGene clusters when comparing ST1 vs ST4 NB MYCN-NA tumors, 309 when comparing ST1 vs ST3, and 633 when comparing ST1 to ST3 and ST4. Using our stringent selection criteria, we found no differentially expressed genes when comparing ST1 vs ST2 or ST2 vs ST3, or ST3 vs ST4, which is not surprising given the closeness of these stages to one another in the PC1 plots ( Figure 1c) . These results establish a stage-specific expression signature in the NB tumors.
GO analysis of the stage-specific expression signatures
To explore the biological processes that are reflected in the differentially expressed genes in the stage-specific expression signature, we analysed the signatures using a novel GO analysis based on PCA. Our motivation for this is as follows. We know that in the PCA plane, different expression patterns correspond to different directions and correlated genes lie in the same direction. We therefore postulated that genes that lie in the same direction have similar molecular functions contained within different biological processes. Therefore, we performed the PCA plots, using samples as variables. Thus, in these plots the genes whose expression profiles are correlated map to similar coordinates because they covary. Figure 2a shows the PCA plot of all 33 680 genes, represented by cyan dots, plotted in the space of PC1 and PC2. The overlaid blue dots represent the clones corresponding to the stage-specific signature common to both ST3 and ST4 compared to ST1 NB MYCN-NA tumors (see Table 1 ) and the overlaid red dots are the clones corresponding to the unique ST4-specific signature in NB MYCN-NA tumors. Thus, both red and blue clones constitute genes differentially expressed in ST4 compared to ST1 NB MYCN-NA tumors. We then divided the PC plot into 360 continuous bins (see Materials and methods and Figure 2a) , and calculated the probability of the enrichment of the differentially expressed genes for a specific GO in each bin. In other words, an enrichment of a specific GO within a bin suggests the involvement of a common biological process for these correlated genes. We found that an overwhelming majority of the biological processes identified in this analysis are involved in cell proliferation:cell cycle, as represented by the probability heat map ( Figure 2b and Table 2 ). This heat map show that the GO terms with the highest statistical significance, all of which involved in cell cycle, are clustered in the area corresponding to the bins located between 2201 and 2701 ( Figure 2 and Table 2 ). This was the same region where the majority of upregulated genes in ST4 (but not ST3) were mapped to, marked by the red dots in Figure 2a . The genes in these bins with increased expression in ST4 NB MYCN-NA tumors higher than 1.5-fold (compared to ST1) were selected and are shown in Table 3 . Genes in this cluster participate in both S phase (GO:0000084) and M phase (GO:0000279) of the cell cycle, as well as the cell cycle checkpoint (GO:0000075). Interestingly, the majority of these cell cycle genes were composed of the genes upregulated in ST4 but not ST3 NB MYCN-NA tumors (only 4.4% of these 159 clones with more than 1.5-fold upregulation are also upregulated in ST3).
MYCN amplification-specific expression signatures and GO analysis Although several genes have been identified that are upregulated by the MYC proteins in vitro (Boon et al., 2001; Fernandez et al., 2003) , the MYCN target genes critical for NB tumorigenesis and tumor progression have not yet been defined. In our analysis, MYCN is found differentially expressed in NB MYCN-AMP tumors, but not in NB MYCN-NA tumors of ST1-4, which is evident from Figure 3a .
In order to identify the MYCN amplification-specific expression signature, a permutation t-test was performed only on ST4 NB MYCN-AMP tumors vs ST4 NB MYCN-NA tumors. This analysis found 691 differentially expressed genes, which are predominantly upregulated (89%). Furthermore, to determine the dependence of this signature on the stage of NB MYCN-AMP tumors, the permutation t-test was also performed on all NB MYCN-AMP (16 of ST4, four of ST3 and one of ST2) tumors vs ST4 NB MYCN-NA tumors. In this analysis, we identified an additional 538 differentially expressed genes (Table 1 ). The PCA plot using these MYCN signature genes shows a nearly complete separation of the amplified samples from ST4 NB MYCN-NA tumors ( Figure 3b ). This PCA plot demonstrates that MYCN amplification is associated with a unique MYCN amplification-specific expression signature, which appears to be independent of the stage of NB.
As with the MYCN-NA stage-specific profiles above, we next explored the biological processes that are reflected in the MYCN-AMP differentially expressed genes. The majority of the biological processes identified in GO analysis was carried out on the MYCN amplification-specific expression signatures involved in protein biosynthesis, as seen in the probability heat map ( Figure 3c and Table 2 ). These results corroborated the finding by Boon et al. (2001) that genes encoding RP are upregulated in NB MYCN-AMP tumors. The expression of RP is increased by 2-fold70.3 (18 genes) compared to ST1 NB MYCN-NA tumors. In addition to Boon's findings, we discovered an increase in the expression of mitochondrial RPs as well (Po5 Â 10 À4 ), with upregulation of 1.6-fold70.2 (10 genes).
Expression levels of the cell cycle genes in NB MYCN-AMP tumors
The GO analyses identified that the predominate biological processes present in the stage and MYCN amplification-specific expression signatures were that of cell proliferation and protein biosynthesis, respectively. Since the cell cycle does not appear as the predominant GO process in NB MYCN-AMP when compared to ST4 Table 3 are further upregulated in MYCN-AMP tumors. We found that these genes were further upregulated in MYCN-AMP tumors compared to ST1: the median is 2.7-fold (as compared to 1.6-fold in ST4NA vs ST1 tumors). It has been demonstrated previously that an association between the expression level of MYCN and the growth potential of NB cells exists (Schweigerer et al., 1990; Negroni et al., 1991; Schmidt et al., 1994) . Using this information, we asked if the MYCN expression level is correlated with the upregulation of the cell cycle genes. We found no difference in the mean level of MYCN expression between ST1 and ST4 NB MYCN-NA tumors ( Figure 3a) and only low levels of correlation (median correlation of 0.3570.12) were observed between MYCN expression and the cell cycle genes (data not shown), suggesting that MYCN expression alone cannot solely be responsible for the upregulation of the cell cycle genes in ST4 NB tumors.
Discussion
In this study, we performed gene expression profiling of 103 NB tumors, ST1-4 with and without MYCN amplification on cDNA microarrays containing 42, 578 elements representing 25, 933 unique UniGene clusters. To our knowledge, this represents the largest number of NB tumor samples profiled on the largest set of cDNA clones (Khan et al., 2001; Berwanger et al., 2002; Alaminos et al., 2003; Mora et al., 2003; McArdle et al., 2004; Takita et al., 2004) . Similar to our study for the MYCN-NA tumors, Berwanger et al. found differentially expressed genes only when comparing 1 vs 4, but found no differences between 2 and 3. However, they found only 24 differentially expressed genes comparing ST1 and ST4, while in the same analysis we found 1434 unique genes. This was, in part, due to their use of a significantly smaller cDNA microarrays containing 4608 elements since the number of samples in both studies was comparable. Different from the previous study (Berwanger et al., 2002) (Table 1 ). This result suggests that NB MYCN-AMP tumors carry a stage-independent expression signature associated with MYCN amplification. These results establish unique stage-and MYCN amplification-specific expression signatures in NB tumors; however, it exemplifies the propensity of these high-dimensional data sets to yield large numbers of differentially expressed genes. Therefore, although Table 1 ). Overlaid in red are the clones corresponding to the unique ST4-specific signature in NB MYCN-NA tumors. Thus, both red and blue clones constitute genes differentially expressed in ST4 compared to ST1 NB MYCN-NA tumors. This figure also illustrates the principle of the PCA-based GO analysis, where a segment (bin) is defined by a 201 angle that is used to select the genes plotted in the PCA space (only differentially expressed genes are considered, red and blue dots). The overlapping segments (bins, total of 360) are created by shifting the 201 angle by 11 starting at the 01 angle of rotation (negative PC1 axis) to the 3601 angle of rotation, which makes a full circle. The angle g defines the 'angle of rotation' formed between the PC1 axis and the 201 segment (bin). The genes in each segment are analysed by the GO analysis as described in Materials and methods. (b) The GO analysis was performed in the space of PC1 and 2 (see a) and the results are presented as a probability heat map, where the red intensity represents the probability of enrichment by random chance for each GO. The vertical axis numbers on the heat map refer to g (angle of rotation in a). The result for the GO term 'process' is shown. The seven-digit numbers on top of the heat map denote the corresponding GO annotation, which are described in Table 2 in the same order cDNA expression profiling in neuroblastoma AL Krasnoselsky et al several gene lists are generated and are likely to be a useful resource for the purpose of data mining, we have sought to discover the underlying processes represented by these differentially expressed genes using the GO database. Our GO analysis of the stage-specific expression signatures discovered an enrichment of biological processes involved in proliferation and specifically in the cell cycle. We show that the cluster of genes corresponding to the cell cycle GO annotations are only present in the ST4 NB MYCN-NA tumors and distinguish them from all lower stage tumors, including ST3. Among the top five upregulated genes in this cluster, two are mapped to the commonly gained region of 17q23-25: survivin (BIRC5, 2.3-fold increased expression) and thymidine kinase (TK1, 2.5-fold). Survivin is an antiapoptotic protein, the expression of which has been shown to correlate with unfavorable histology and poor prognosis, to and promote survival of NB cell lines (Islam et al., 2000) . Its expression is known to be (Li et al., 1998) . In addition, this cluster includes all three groups of kinases involved in the regulation of the mitotic spindle checkpoint: NIMA-related kinases (Nek2), Aurora-A (STK15) and Polo kinases (PLK1, PLK4). The Aurora-A gene encodes a centrosomeassociated kinase, which has been reported amplified and overexpressed in NB (Zhou et al., 1998) , as well as in several cancers (Ewart-Toland et al., 2003) . Its overexpression leads to centrosome amplification, abnormal regulation of the spindle checkpoint, chromosomal instability and transformation in mammalian cells. The majority of the genes in the cell cycle cluster are upregulated to the same or higher degree in the NB MYCN-AMP tumors. Among them, survivin is upregulated fourfold in NB MYCN-AMP tumors compared to ST1. In addition, we found that a partner of survivin (Aurora-B) in a complex regulating the kinetochore is upregulated in NB MYCN-AMP tumors, where Aurora-B requires survivin for its proper localization. Recently, Sugihara et al. (2004) showed that MYCN alone does not induce centrosome hyperamplification. However, in combination or followed by induced DNA damage, MYCN overexpression contributes to the centrosome hyperamplification, suggesting that higher levels of MYCN expression leads to disregulation of centrosome maintenance. Our findings extend this observation further in pointing to a set of genes involved in centromere regulation. Our analysis of MYCN amplification-specific expression signature corroborated the finding by Boon et al. (2001) that genes encoding RP are upregulated in NB MYCN-AMP tumors. In addition to Boon's findings, we discovered an increase in the expression of mitochondrial RP. It is possible that increased expression of RP is mediated by Dyskerin (DKC1), which is a direct target of MYCN (Boon et al., 2001) and is a nuclear protein responsible for some early steps in ribosomal RNA processing (Ruggero and Pandolfi, 2003) . DKC1 is upregulated (1.9-fold in NB MYCN-AMP compared to ST4 NB MYCN-NA tumors and 2.5-fold compared to ST1) in an MYCN-dependent manner in both NB MYCN-NA and NB MYCN-AMP tumors (Pearson's correlation À0.77).
In conclusion, we have established stage-and MYCNamplification-specific gene expression signatures and identified an association between the patterns of expression and the biological processes associated with an aggressive NB phenotype. Using our PCA-based statistical approach, we identified a specific subset of cell cycle and/or chromosome segregation genes that distinguish ST4 NB tumors from all lower stage tumors, including ST3. Furthermore, the control of the kinetochore assembly emerges from the GO analysis as one of the key biological processes associated with an aggressive NB phenotype. Additionally, we find that these genes are further upregulated or increased in expression in the most aggressive NB MYCN-AMP compared with the ST4 MYCN-NA tumors. Therefore, these cell cycle genes constitute important genes for biological validation and potential therapeutic targets in aggressive NB. Figure 2a) and the results are presented as a probability heat map, where the red intensity represents the probability of enrichment by random chance for each cytoband. The vertical axis numbers on the heat map refer to g (angle of rotation in Figure 2a) . The result for the GO term 'process' is shown. The seven-digit numbers on top of the heat map denote the corresponding GO annotation, which are described in Table 2 in the same order Wei and Khan (2002) . The reference RNA used in these studies consisted of equal portions of total RNA obtained from the seven human cancer cell lines (Wei et al., 2004) . Total RNA was amplified as described by Wang et al. (2000) ; hybridization and washing of the microarrays were performed as described by Hegde et al. (2000) . The microarrays used in these studies consisted of 42 578 cDNA clones, representing 25 933 UniGene clusters. The ratio data were normalized using quadrant normalization with minor modifications and quality filtered (Chen et al., 2002) , such that the average quality for a gene expression vector did not fall below 0.95. The total number of clones after filtering resulted in 33 680 clones that were used for the analyses described in this paper.
Permutation t-test and other statistical tests
To control a false-positive rate (FDR), a permutation t-test was performed with 1000 permutation cycles per test. The adjusted probability was calculated as the integrated probability for each tail. A paired t-test for each gene was performed as follows. First, two groups were formed according to the chosen partitioning of the full data set. Each group was filtered for the entries that did not meet the quality criterion, and then a homogeneity of variance test was performed for the two sample populations. For the populations with equal variance but unequal sample size, the Welch-Strathmore adjustment was performed to estimate the degrees of freedom (see, e.g. Zar, 1999) . A Kolmogorov-Smirnov test was used to evaluate the normality of each sample population. When the normality distribution assumption was violated (o2% of all cases), a two-sample Kolmogorov-Smirnov test was performed instead of the t-test. A gene was considered differentially expressed when adjusted, Po0.05. This false-discovery rate of 5% refers to the set of genes derived in the permutation t-test. Calculations of ANOVA, Pearson's correlation and F-test for the homogeneity of variance were carried out as described elsewhere (Zar, 1999) .
Principal component analysis
The gene expression matrix X of the dimensions n Â p was assembled with n rows containing individual gene expression vectors and p columns representing tumor expression profiles. The mean expression vector was subtracted by row centering the matrix. PCs were derived through the singular value decomposition (SVD) of the variance-covariance matrix of the filtered data set (33 680 clones Â N tumors, where Np103). All computations were carried out in MATLAB (MathWorks Inc., Natick, MA, USA). In order to avoid ambiguity in the definitions of PCs, we refer to the eigenvectors derived in SVD as PCs, and newly derived variables as projections on PCs. If SVD of a matrix X is presented as X ¼ USV T , where X is the centered matrix of gene expression, then the columns of V I represent PCs in our definition. The vectors defined by V T are referred to as eigentumors and the dimensions are defined by U as eigengenes (similar to the eigenarray nomenclature defined in Alter et al., 2000) .
For Figure 1c , we first calculated the median value of gene expression for the 6103 ANOVA genes (see above) for each of the four stages, and then performed PCA.
Probabilistic GO analysis
For all the clones that passed our quality filters (33 680 clones), projections of each clone on the plane formed by PC1 and PC2 were considered. Each clone, therefore, is represented by a coordinate pair [pc 1i ,pc 2i ] on the plane. The genes in the PCA plane were binned such that each bin is defined by a 201 angle segment that is used to select the genes plotted in the PCA space. The use of a 201 angle was determined by as follows. Since our clones on the microarrays were redundant (33 680 clones representing 25 933 UniGene clusters), we first calculated the angle between multiple clones that represent a single UniGene cluster. Then, we calculated the average standard deviation for those angles and doubled it (2 Â s.d.) and found that 2 Â s.d. of the angles was approximately a 201 angle. Thus, this angle will contain the majority of clones that represents a single UniGene cluster in the plane of PC1 and PC2. The overlapping segments (bins, total of 360) are created by shifting the 201 angle by 11 starting at 01 angle of rotation to 3601 angle of rotation, which makes a full circle, see Figure 2a .
We analysed groups of genes preselected by the methods of analysis carried out in this study for an over-representation or enrichment of specific GO annotations. GO provides annotation for 47% of the clones in our experiment. From the directed acyclic graph structure of the GO, each node of annotation is coupled to over-or underlying nodes via an 'isa' or 'part-of' relation. A clone mapped to any given annotation is therefore also associated with the parent nodes. The GO provides a link from LocusLink identifiers to GO terms. We therefore mapped each clone to a UniGene cluster and used the locus link identifier to associate the clones with GO terms.
For the probabilistic analysis of GO annotations (Alter et al., 2000; Ashburner et al., 2000) , each bin derived in PCA-based partitioning of the genes was analysed for over-representation of GO terms. For each GO term, the number of associated genes within each bin was compared with the number expected by random chance. By integration of the hypergeometric probability distribution, we estimated a P-value. We applied the Bonferroni correction to the threshold for significance by counting the number of GO annotations that were occupied by more than 50 genes in the set of differentially expressed unique genes. This resulted in an unadjusted P-value of 10 À4 as a cutoff probability corresponding to 5% false-discovery rate in the final list of significant GO terms. 
